YOLFTbeta
AlzeCure Pharma

AlzeCure Pharma

ALZCUR · ST · Healthcare / Biotechnology

6.40SEK-0.12 (-1.84%)

Price History

Full chart

Market Stats

Previous Close6.52
Open6.40
Day Range6.32 – 6.50
52-Week Range1.16 – 8.68
Volume172.49K
Market Cap788.31M
P/E (TTM)20.79
Forward P/E0.00
EPS0.33
Dividend Yield0.00%
Beta-0.07
50-Day Avg7.19
200-Day Avg3.66

About

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pain indications; and ACD137 negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications, which is in preclinical phase. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Martin Jönsson
  • Employees10
  • HeadquartersHälsovägen 7, Huddinge, Sweden, 141 57, Sweden
  • Websitehttps://www.alzecurepharma.se

Leadership

  • Mr. Martin JönssonChief Executive Officer · b. 1968
  • Ms. Birgitta LundvikChief Financial Officer · b. 1967
  • Mr. Johan SandinChief Scientific Officer · b. 1970
  • Dr. Marta Segerdahl Storck M.D., Ph.D.Chief Medical Officer · b. 1956
  • Dr. Cecilia Wadell MSc Pharm, Ph.D.Head of Development

Financials

Income Statement

Currency: SEK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue883.38K00000000
Growth (%)--100.00%-------
Cost of Revenue8.00K104.00K44.79M495.00K576.00K570.00K476.00K293.00K1.27M
Gross Profit875.38K-104.00K-44.79M-495.00K-576.00K-570.00K-476.00K-293.00K-1.27M
Gross Margin99.09%--------
Operating Expense11.64M35.79M6.12M71.08M77.35M55.87M37.79M36.16M48.10M
Operating Income-10.77M-35.89M-50.91M-71.58M-77.93M-56.44M-38.26M-36.45M-49.37M
Operating Margin-1218.83%--------
EBITDA-10.81M-36.03M-50.57M-70.87M-77.20M-55.67M-37.87M-35.70M-48.10M
EBITDA Margin-1224.15%--------
Net Income-10.82M-35.98M-51.01M-71.37M-77.78M-56.04M-37.17M-35.23M-47.65M
Net Income Margin-1225.06%--------
R&D10.97M36.83M44.79M62.36M66.72M46.18M27.23M24.69M36.22M
R&D as % of Total Revenue1242.15%--------
Interest Expense55.00K92.00K149.00K1.00K1.00K4.00K7.00K19.00K273.00K
Interest Expense % of Total Revenue6.23%--------

Balance Sheet

Currency: SEK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets55.97M237.78M186.75M117.83M45.65M70.84M32.00M34.44M59.04M
Total Liabilities4.15M4.61M4.75M7.07M12.67M10.35M8.23M8.25M26.12M
Total Equity51.83M233.17M182.01M110.75M32.97M60.48M23.77M26.18M32.92M
Cash53.95M234.55M182.50M112.43M41.74M25.58M29.10M31.50M50.34M
Total Debt--------5.12M
Net Debt-53.95M-234.55M-182.50M-112.43M-41.74M-25.58M-29.10M-31.50M-45.22M

Cash Flow

Currency: SEK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-8.42M-36.27M-50.28M-69.51M-70.64M-99.91M3.06M-35.12M-34.59M
Investing Cash Flow-274.00K-459.00K-1.46M-671.00K-54.00K07.00K-124.00K0
Financing Cash Flow62.65M217.33M-304.00K114.00K83.75M83.75M459.00K37.65M53.43M
Capital Expenditure267.00K459.00K1.46M671.00K54.00K00124.00K0
Free Cash Flow-8.69M-36.73M-51.75M-70.18M-70.69M-99.91M3.06M-35.25M-34.59M
FCF to OCF103.17%101.27%102.91%100.97%100.08%100.00%100.00%100.35%100.00%

Earnings

Report DateFeb 28, 2019Apr 29, 2019Aug 22, 2019Nov 15, 2019Feb 28, 2020May 5, 2020Aug 25, 2020Nov 17, 2020Feb 26, 2021May 5, 2021Aug 25, 2021Nov 10, 2021Feb 24, 2022May 5, 2022Aug 24, 2022Nov 10, 2022Feb 24, 2023May 4, 2023Aug 24, 2023Nov 9, 2023Feb 27, 2024Apr 25, 2024Aug 26, 2024Nov 11, 2024Feb 27, 2025May 5, 2025Aug 26, 2025Nov 11, 2025Feb 25, 2026May 6, 2026Aug 26, 2026
EPS Estimate-------------------------------
EPS Actual-0.41-0.29-0.26-0.34-0.40-0.36-0.48-0.57-0.47-0.61-0.42-0.44-0.58-0.33-0.43-0.22-0.22-0.15-0.16-0.12-0.16-0.15-0.12-0.08-0.11-0.11-0.10-0.09-0.15-0.170.58
Surprise-------------------------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--

Key Statistics & Ratios

Market Cap788.31M
Enterprise Value852.67M
Trailing P/E20.79
Forward P/E0.00
Price / Sales8.10
Price / Book9.45
EPS0.33
Book Value0.663
Revenue (TTM)97.33M
Gross Profit (TTM)97.33M
EBITDA31.47M
Profit Margin31.56%
Operating Margin82.44%
Return on Equity62.86%
Return on Assets27.25%
Shares Outstanding114.91M
Shares Float92.15M
Beta-0.07
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%